These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 26260815)

  • 1. Tuberculosis preventive chemotherapy: the times they are a-changin'.
    Dedicoat M; Lange C
    Int J Tuberc Lung Dis; 2015 Sep; 19(9):1002. PubMed ID: 26260815
    [No Abstract]   [Full Text] [Related]  

  • 2. Short-course isoniazid plus rifapentine therapy for latent tuberculosis in Brazil.
    Croda J
    Rev Soc Bras Med Trop; 2015; 48(5):505-6. PubMed ID: 26516957
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of treating latent tuberculous infection: a step towards elimination?
    Diel R; Loddenkemper R; Sotgiu G; Migliori GB
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1515. PubMed ID: 24200259
    [No Abstract]   [Full Text] [Related]  

  • 4. Update on cost-effectiveness of a 12-dose regimen for latent tuberculous infection at new rifapentine prices.
    Shepardson D; MacKenzie WR
    Int J Tuberc Lung Dis; 2014 Jun; 18(6):751. PubMed ID: 24903950
    [No Abstract]   [Full Text] [Related]  

  • 5. Three months of once-weekly isoniazid plus rifapentine (3HP) in treating latent tuberculosis infection is feasible in patients with rheumatoid arthritis.
    Chen YM; Liao TL; Chen HH; Chen DY
    Ann Rheum Dis; 2018 Nov; 77(11):1688-1689. PubMed ID: 29674320
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of 12-dose LTBI regimen improved following advocacy to lower the price of rifapentine.
    Frick M; Seaworth B; McKenna L; Elnour T; Lee C
    Int J Tuberc Lung Dis; 2014 Nov; 18(11):1386. PubMed ID: 25299876
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of latent tuberculosis with 12 weeks isoniazid/rifapentine in clinical practice.
    Fröberg G; Jansson L; Bruchfeld J
    Eur Respir J; 2019 Feb; 53(2):. PubMed ID: 30409821
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of latent tuberculosis infection.
    Parekh MJ; Schluger NW
    Ther Adv Respir Dis; 2013 Dec; 7(6):351-6. PubMed ID: 24056289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latent Mycobacterium tuberculosis infection.
    Getahun H; Matteelli A; Chaisson RE; Raviglione M
    N Engl J Med; 2015 May; 372(22):2127-35. PubMed ID: 26017823
    [No Abstract]   [Full Text] [Related]  

  • 10. Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates.
    de Castilla DL; Rakita RM; Spitters CE; Narita M; Jain R; Limaye AP
    Transplantation; 2014 Jan; 97(2):206-11. PubMed ID: 24142036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
    Simkins J; Abbo LM; Camargo JF; Rosa R; Morris MI
    Transplantation; 2017 Jun; 101(6):1468-1472. PubMed ID: 27548035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immigrants with latent tuberculosis infection: a moving target?
    Chee CB
    Int J Tuberc Lung Dis; 2013 Mar; 17(3):287. PubMed ID: 23407217
    [No Abstract]   [Full Text] [Related]  

  • 13. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
    Bliven-Sizemore EE; Sterling TR; Shang N; Benator D; Schwartzman K; Reves R; Drobeniuc J; Bock N; Villarino ME;
    Int J Tuberc Lung Dis; 2015 Sep; 19(9):1039-44, i-v. PubMed ID: 26260821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe hypertension after initiation of rifapentine/isoniazid for latent tuberculosis in renal transplant candidates.
    Simkins J; Morris MI; Abbo LM; Camargo JF
    Transpl Int; 2017 Jan; 30(1):108-109. PubMed ID: 28032405
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection.
    Pina JM; Clotet L; Ferrer A; Sala MR; Garrido P; Salleras L; Domínguez A
    Respir Med; 2013 May; 107(5):768-77. PubMed ID: 23490222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Question 1: what are the options for treating latent TB infection in children?
    Gwee A; Coghlan B; Curtis N
    Arch Dis Child; 2013 Jun; 98(6):468-74. PubMed ID: 23661667
    [No Abstract]   [Full Text] [Related]  

  • 17. Isoniazid-induced acute liver failure during preventive therapy for latent tuberculosis infection.
    Miyazawa S; Matsuoka S; Hamana S; Nagai S; Nakamura H; Nirei K; Moriyama M
    Intern Med; 2015; 54(6):591-5. PubMed ID: 25786447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability of rifampin monotherapy for latent tuberculosis infection in children.
    Daskalaki I; Byun J; Dogbey MC; Tolbert-Warren C; Watson BM
    Pediatr Infect Dis J; 2011 Nov; 30(11):1014-5. PubMed ID: 21997666
    [No Abstract]   [Full Text] [Related]  

  • 19. Tuberculosis: which drug regimen and when.
    Hall J; Elliott C
    J Fam Pract; 2015 Jan; 64(1):27-33. PubMed ID: 25574509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifapentine and isoniazid for latent tuberculosis.
    Johnson JR
    N Engl J Med; 2012 Apr; 366(15):1447. PubMed ID: 22494127
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.